BCIQ Profiles

Company Profile Report

Rain raises $18M to advance tarloxotinib in NSCLC

Rain Therapeutics Inc. (Fremont, Calif.) closed a tranched $18.4 million series A round led by Biotechnology Venture Fund (BVF), with participation from fellow new investors Perceptive Advisors, Auckland UniServices' Inventors Fund and FMB Research’s Franklin Berger. Other undisclosed private investors also participated.

Rain co-founder, CEO and Chairman Avanish

Read the full 477 word article

How to gain access

Continue reading with a
two-week free trial.